JP4593048B2 - 分岐型ポリアルキレングリコール類 - Google Patents

分岐型ポリアルキレングリコール類 Download PDF

Info

Publication number
JP4593048B2
JP4593048B2 JP2001548589A JP2001548589A JP4593048B2 JP 4593048 B2 JP4593048 B2 JP 4593048B2 JP 2001548589 A JP2001548589 A JP 2001548589A JP 2001548589 A JP2001548589 A JP 2001548589A JP 4593048 B2 JP4593048 B2 JP 4593048B2
Authority
JP
Japan
Prior art keywords
compound
group
mmol
added
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001548589A
Other languages
English (en)
Japanese (ja)
Inventor
基生 山▲崎▼
敏行 須澤
達也 村上
紀子 櫻井
錦也 山下
真由美 向井
隆 ▲桑▼原
聡 太田
一郎 三木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of JP4593048B2 publication Critical patent/JP4593048B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
JP2001548589A 1999-12-24 2000-12-22 分岐型ポリアルキレングリコール類 Expired - Fee Related JP4593048B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP36631299 1999-12-24
PCT/JP2000/009159 WO2001048052A1 (fr) 1999-12-24 2000-12-22 Glycols de polyalkylene ramifies

Publications (1)

Publication Number Publication Date
JP4593048B2 true JP4593048B2 (ja) 2010-12-08

Family

ID=18486472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001548589A Expired - Fee Related JP4593048B2 (ja) 1999-12-24 2000-12-22 分岐型ポリアルキレングリコール類

Country Status (7)

Country Link
US (1) US7691367B2 (de)
EP (1) EP1270642B1 (de)
JP (1) JP4593048B2 (de)
AT (1) ATE522563T1 (de)
AU (1) AU2223401A (de)
CA (1) CA2395254C (de)
WO (1) WO2001048052A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002217981A1 (en) * 2000-11-30 2002-06-11 Cornerstone Pharmaceuticals, Inc. Water-soluble polymer conjugates of triazine derivatives
ATE471956T1 (de) * 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
AU2003303635B2 (en) 2002-12-26 2009-07-23 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CA2511549A1 (en) * 2002-12-31 2004-07-22 Medtronic Minimed, Inc. Hydrophilic cross-linking agents for use in enzymatic sensors
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
KR101025143B1 (ko) * 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
CA2519092C (en) * 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
CN101880326B (zh) * 2003-08-25 2018-02-16 东丽株式会社 干扰素‑β复合物
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
EP1771066A2 (de) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5515224B2 (ja) 2007-02-28 2014-06-11 日油株式会社 多分岐鎖ポリオキシアルキレン誘導体
DK2144923T3 (da) 2007-04-03 2013-05-13 Biogenerix Ag Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
EP2236521A4 (de) * 2007-12-29 2013-07-10 Biosteed Gene Expression Tech Co Ltd Durch polyethylenglykol vom y-typ modifizierter g-csf und verfahren zu dessen herstellung und verwendung davon
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
PL2272875T3 (pl) * 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania
JP5767207B2 (ja) 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
CN110591079B (zh) * 2018-06-13 2022-08-02 厦门赛诺邦格生物科技股份有限公司 单官能化非线性聚乙二醇的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0215041A (ja) * 1988-03-14 1990-01-18 Sandoz Ag アルキル及びアルケニルカテコール類のカルボキシレート類及びエトキシレート類
JPH04108827A (ja) * 1990-08-28 1992-04-09 Sumitomo Pharmaceut Co Ltd 新規なポリエチレングリコール誘導体修飾ペプチド
JPH08510255A (ja) * 1993-05-10 1996-10-29 プロティン．デリバリー．インコーポレイテッド 接合−安定化ポリペプチド組成物
JPH09504299A (ja) * 1993-10-27 1997-04-28 エンゾン，インコーポレーテッド 非抗原性分枝ポリマー複合体
JPH10502401A (ja) * 1994-06-24 1998-03-03 エンゾン，インコーポレーテッド 非抗原性アミン誘導ポリマーおよびポリマー複合体
JPH11514396A (ja) * 1995-09-15 1999-12-07 ブラッコ・エッセ・ピ・ア 選択的に官能化しうるデスデンドリマー類

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157384A (en) * 1972-01-28 1979-06-05 Wilkinson Sword Limited Compositions having a physiological cooling effect
JP2997004B2 (ja) 1989-05-26 2000-01-11 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
EP0788375A2 (de) * 1994-11-09 1997-08-13 Robin Ewart Offord Funktionstüchtige polymere für lagespezifische bindung
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE19640092A1 (de) * 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
EA003789B1 (ru) 1998-04-28 2003-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0215041A (ja) * 1988-03-14 1990-01-18 Sandoz Ag アルキル及びアルケニルカテコール類のカルボキシレート類及びエトキシレート類
JPH04108827A (ja) * 1990-08-28 1992-04-09 Sumitomo Pharmaceut Co Ltd 新規なポリエチレングリコール誘導体修飾ペプチド
JPH08510255A (ja) * 1993-05-10 1996-10-29 プロティン．デリバリー．インコーポレイテッド 接合−安定化ポリペプチド組成物
JPH09504299A (ja) * 1993-10-27 1997-04-28 エンゾン，インコーポレーテッド 非抗原性分枝ポリマー複合体
JPH10502401A (ja) * 1994-06-24 1998-03-03 エンゾン，インコーポレーテッド 非抗原性アミン誘導ポリマーおよびポリマー複合体
JPH11514396A (ja) * 1995-09-15 1999-12-07 ブラッコ・エッセ・ピ・ア 選択的に官能化しうるデスデンドリマー類

Also Published As

Publication number Publication date
EP1270642A4 (de) 2006-01-18
ATE522563T1 (de) 2011-09-15
CA2395254A1 (en) 2001-07-05
WO2001048052A1 (fr) 2001-07-05
EP1270642A1 (de) 2003-01-02
US20030219404A1 (en) 2003-11-27
EP1270642B1 (de) 2011-08-31
AU2223401A (en) 2001-07-09
US7691367B2 (en) 2010-04-06
CA2395254C (en) 2010-05-11

Similar Documents

Publication Publication Date Title
JP4593048B2 (ja) 分岐型ポリアルキレングリコール類
US7547765B2 (en) Branched polyalkylene glycols
ES2866674T3 (es) Conjugados de una fracción de IL-2 y un polímero
KR102209395B1 (ko) 새로운 약물-단백질 접합체
AU2021258008A1 (en) Conjugates of an IL-15 moiety and a polymer
JP2022163194A (ja) Ｉｌ－７部分とポリマーとのコンジュゲート
JP2009503111A (ja) Ｇ−ｃｓｆ部分および重合体の複合体
JP2002517515A (ja) 二価抗体フラグメント
JP4142569B2 (ja) 軟膏剤
JP2006517995A (ja) 活性化されたポリエチレングリコールエステル類
WO2005085283A1 (ja) 修飾インターロイキン−１１及びそれを含有する医薬組成物
KR20030045415A (ko) Ｇ-ｃｓｆ와 폴리에틸렌글리콜 유도체의 배합체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100818

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100915

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130924

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130924

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140924

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees